´
265
I. Sovic et al. / Journal of Molecular Structure 1006 (2011) 259–265
Supplementary material
CCDC 799224–799226 contains the supplementary crystallo-
graphic data for this paper. These data can be obtained free of
Cambridge Crystallographic Data Centre (CCDC), 12 Union Road,
Cambridge CB2 1EZ, UK; fax:+44 (0)1223 336033; email:
deposit@ccdc.cam.ac.uk].
Acknowledgements
The Ministry of Science, Education and Sport of the Republic of
Croatia (Grant Nos. 125-0982464-1356, 119-1193079-3069, 335-
0000000-3532 and 119-1191342-1083) supported this work.
References
[1] D. Berger, R. Citarella, M. Dutia, L. Greenberger, W. Hallett, R. Paul, D. Powell, J.
Med. Chem. 42 (1999) 2145.
Fig. 7. Absorption spectra of 6–9 in ethanol at the concentration of
[2] L.A. Masterson, S.J. Croker, T.C. Jenkins, P.W. Howard, D.E. Thurston, Bioorg.
Med. Chem. Lett. 14 (2004) 901.
[3] C. Shinji, S. Maeda, K. Imai, M. Yoshida, Y. Hashimoto, H. Miyachi, Bioorg. Med.
Chem. 14 (2006) 7625.
2.0 Â 10À5 mol dmÀ3
.
[4] T.M. Percino, J.C. Basurto, K.S. Alavés Carbajal, N. Valle-Sandoval, J. Trujillo
Ferrara, J. Mex. Chem. Soc. 53 (2009) 1.
[5] N. Gueven, J. Luff, C. Peng, K. Hosokawa, S.E. Bottle, M.F. Lavin, Free Radical
Biol. Med. 41 (2006) 992.
Table 5
Electronic absorption data of 6–9 recorded in ethanol at the concentration of 2 Â 10À5
mol dmÀ3
.
[6] G.W. Muller, H.-W. Man, US Patent 7495,237 B2 2008.
[7] N.G. Kundu, M.W. Khan, R. Mukhopadhyay, J. Ind. Chem. Soc 78 (2001) 671.
[8] S. Van Goethem, P. Van, V. der Veken, A. Dubois, A.-M. Soroka, X. Lambeir, A.
Chen, S. Haemers, I. Scharpe, K. De Meester, K. Augustyns, Bioorg. Med. Chem.
Lett. 18 (2008) 4159.
[9] W.-T. Jiaang, J.-S. Chen, T. Hsu, S.-H. Wu, C.-H. Chien, C.-N. Chang, S.-P. Chang,
S.-J. Lee, X. Chen, Bioorg. Med. Chem. Lett. 15 (2005) 687.
[10] J.-C. Souvie, C. Fugire, J.-P. Lecouve, US Patent 6320,058 B2 2001.
[11] E. Meggers, G.E. Atilla-Gokcumen, H. Bregman, J. Maksimoska, S.P. Mulcahy, N.
Pagano, D.S. Williams, Synlett 8 (2007) 1177.
[12] J. Kaizer, B. Kripli, G. Speier, L. Parkanyi, Polyhedron 28 (2009) 933.
[13] M. Horiuchi, K. Ohnishi, N. Iwase, Y. Nakajima, K. Tounai, M. Yamashita, Y.
Yamada, Biosci. Biotechnol. Biochem. 67 (2003) 1580.
[14] A. Pugin, K.E. Burdeska, A. Staub, US Patent 3484,454 1969.
[15] B. Lotsch, US Patent 4719,300 1988.
Compound
6
kabs,max (nm)
e
 103 (dm3 molÀ1 cmÀ1
)
284
237
210
288
239
210
306
231
209
312
234
209
8.7
23.8
36.5
10.1
26.9
40.3
17.7
21.6
26.0
18.3
24.8
27.0
7
8
9
[16] Y. Mulyana, C.J. Kepert, L.F. Lindoy, J.C. McMurtie, Eur. J. Inorg. Chem (2005)
2470.
[17] J.M. Chitanda, D.E. Prokopchuk, J.W. Quail, S.R. Foley, Dalton Trans. (2008)
6023.
[18] J.M. Chitanda, J.W. Quail, S.R. Foley, J. Organomet. Chem. 694 (2009) 1542.
[19] M. Broering, C. Kleeberg, Inogr. Chim. Acta 362 (2009) 1065.
[20] E.V. Pankratova, G.N. Rodionova, B.E. Zaitsev, V.A. Titkov, Chem. Heterocycl.
Comp. 13 (1977) 54.
Table 6
Inhibitory effects of compounds 6–9 on the growth of malignant tumor cell lines and
normal human fibroblasts (WI 38).
IC50 (l
M)a
[21] A. Cul, A. Daich, B. Decroix, G. Sanz, L. Van Hijfte, Tetrahedron 60 (2004) 11029.
[22] H. Yoshida, H. Fukushima, T. Morishita, J. Ohshita, A. Kunai, Tetrahedron 63
(2007) 4793.
Compound
Cell lines
HeLa
MCF-7
HepG2
SW620
MiaPaCa-2
WI38
[23] E.R. Bonfield, C.-J. Li, Adv. Synth. Catal. 350 (2008) 370.
[24] T. DoMinh, A.L. Johnson, J.E. Jones, P.P. Senise Jr, J. Org. Chem. 42 (1977) 4217.
[25] R. Grigg, H.Q.N. Gunaratne, V. Sridharan, Chem. Commun. (1985) 1183.
[26] S.M. Allin, C.C. Hodkinson, N. Taj, Synlett (1996) 781.
[27] I. Takahashi, T. Kawakami, E. Hirano, H. Yokota, H. Kitajima, Synlett (1996)
353.
6
7
8
9
>100
59.97
>100
>100
>100
88.14
>100
95.14
79.29
46.81
42.91
79.88
>100
45.12
85.35
>100
>100
56.80
>100
>100
>100
58.13
82.61
>100
a
IC50; the concentration that causes a 50% reduction of the cell growth.
[28] J.M. Chitanda, D.E. Prokopchuk, J.W. Quail, S.R. Foley, Organometallics 27
(2008) 2337.
[29] Oxford Diffraction, CrysAlis CCD and CrysAlis RED. Version 1.170. Oxford
Diffraction Ltd., Wroclaw, Poland, 2003.
[30] G.M. Sheldrick, Acta Cryst. A64 (2008) 112.
as well as their antiproliferative activity. Novel 1-iminoisoindoline
derivatives were prepared from phthalaldehyde and corresponding
amines in absolute ethanol. The presence of nitrogen in substitu-
ents on the isoindoline system was found to greatly increase the
compounds’ thermal stability. Structural analysis showed that
conformations of the prepared compounds are not the same in
solution and solid state. Prepared compounds were also tested on
their antiproliferative activity in vitro on five human tumor cell
lines as well as on normal (diploid) human fibroblasts. Those re-
sults are guidelines for further structural optimization studies.
[31] L.J. Farrugia, J. Appl. Cryst. 32 (1999) 837.
[32] STARe Software V.9.01., MettlerToledo GmbH, 2006.
[33] I. Takahashi, K. Nishiuchi, R. Miyamoto, M. Hatanaka, H. Uchida, K. Isa, A.
Sakushima, S. Hosoi, Lett. Org. Chem. 2 (2005) 40.
[34] L.-N. Zhu, S. Gao, L.H. Huo, H. Zhao, Acta Cryst. E63 (2007) o4111.
[35] M. Akkurt, S.O. Yildirim, S.S. Al-Shihry, O. Buyukgungor, Acta Cryst. E62 (2006)
o2226.
[36] I. Takahashi, R. Miyamoto, K. Nishiuchi, M. Hatanaka, A. Yamano, A.
Sakushima, S. Hosoi, Heterocycles 63 (2004) 1267.
[37] J.M. Chitanda, J.W. Quail, S.R. Foley, Acta Cryst. E64 (2008) m907.
[38] V. Stilinovic´, D. Cincˇic´, B. Kaitner, Acta Chim. Slov. 55 (2008) 874.